CN102579478A - Application of sodium hyaluronate to preparation of medicines - Google Patents
Application of sodium hyaluronate to preparation of medicines Download PDFInfo
- Publication number
- CN102579478A CN102579478A CN2012100901672A CN201210090167A CN102579478A CN 102579478 A CN102579478 A CN 102579478A CN 2012100901672 A CN2012100901672 A CN 2012100901672A CN 201210090167 A CN201210090167 A CN 201210090167A CN 102579478 A CN102579478 A CN 102579478A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- acid sodium
- application
- preparation
- allergic rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of sodium hyaluronate to the preparation of medicines. On the basis of the administration of an upper respiratory tract, allergic rhinitis is treated by using the sodium hyaluronate; and the types of medicaments and a method for treating allergic rhinitis by using the sodium hyaluronate are provided. A new purpose is explored for the sodium hyaluronate, a new application field is developed, and the sodium hyaluronate is non-toxic, does not have a side effect and has an obvious curative effect during the treatment of allergia rhinitis.
Description
Technical field
The present invention relates to the new purposes of hyaluronic acid sodium, be specifically related to hyaluronic acid sodium the application in preparation medicine of hyaluronic acid sodium, belong to medical technical field in treatment of allergic rhinitis.
Background technology
Hyaluronic acid sodium (SH) claim hyaluronate sodium again; Be extensively to be present in the intravital biological active substances of animal and human; Being to repeat crosslinked and a kind of macromolecule aminoglycan that form by N-acetylglucosamine and D-glucuronic acid, is the main component that constitutes extracellular matrix and intercellular stroma.Along with deepening continuously of research, find the conjugated protein and receptor of SH ability, all bringing into play important effect aspect generation, reparation, cell regulate and control and the angiogenesis of tissue, therefore, SH is in the field of medicaments extensive use.The application of SH in medicine at present is following.
Application in field of ophthalmology: the corneal epithelium wound healing, SH has been developed to into promoting the medicine of corneal wound healing in the treatment xerophthalmia, like SH sodium eye drop at present.Because the SH intramolecularly can be possessed numerous hydrones, thereby has excellent water-retaining property, can protect cornea moist; In cataract operation, SH is used to keep operative space at present, the protection endothelial layer.
Application in the orthopaedics field: osteoarthritis is used for the intra-articular injection treatment osteoarthritis with SH as the articular cartilage protective agent, and obtains good efficacy.Rheumatoid arthritis, the patient carries out joint cavity injection SH, 1 time weekly; Continuous 5 weeks; Clinical parameters such as level to arthralgia, inflammation, synovial fluid volume and several kinds of chemical substances carry out tracking and measuring then, and the result shows the significantly improvement of each item index, and sb.'s illness took a favorable turn.
The application of surgical field: cystitis, SH is to bladder mucosa epithelium healing and to the effect of bladder fiber.The capacity of finding bladder in the treatment group increases to some extent, and the epithelial defect area reduces to some extent.Find also simultaneously that SH can promote the bladder mucosa epithelial wound healing but suppress the growth of bladder fiber.Tissue adhesion, application of SH prevent that tissue adhesion from starting from the nineties in 20th century, and a large amount of experiments and clinical practice show, the biosystem that the adhesion of SH scalable forms, prevention and minimizing postoperative tissue adhesion.
Preserving moisture and protecting skin function: SH has the title of " molecule sponge ", can absorb and keep himself weight 500-1000 water doubly, and generate gel, forms one deck hydration shell, and horny layer is kept moisture-keeping function, prevents xerosis cutis, produces skin care effect.In addition, the SH hydration shell also have ventilative and non-closure property, result produce general closed emollient the skin moistening function that can not compare.SH also can help to prevent that ossein is converted into non-dissolved state by dissolved state through forming glutinous bullet liquid and being filled in the subcutaneous collagen fibre, and with protein complex skin is produced collaborative moisture-keeping function.
Promote the wound healing function: after body received injuries such as wound, operation wound, scald and cold injury, endogenous macromolecule SH was one of main bioactive substance that at first arrives the wound.Under the effect of SH enzyme, SH degrades rapidly, and excites wound to repair gradually.SH can also strengthen the activity of thrombin; The formation of accelerating fibers sludged blood and stopping blooding; And the entering that can promote monocytic pathology phagocytosis and epidermis cell with stick and fibroblasts proliferation and migration; Prevent that inflammation from oozing out, directly promoted growth, differentiation, reconstruction and the structure repair of cell.Simultaneously,, can promote that cell moves, keep the constant of wound circumference skin water environment, for wound healing provides advantage through enlarging the intercellular space because the height of SH is preserved moisture and hydrating capacity.
Pharmaceutical carrier function: SH mainly produces medicament slow release and promotes drug transdermal to absorb two kinds of effects as pharmaceutical carrier.
Summary of the invention
The object of the present invention is to provide the application of hyaluronic acid sodium in the preparation medicine; Through the upper respiratory tract administration; Use the effect of sodium hyaluronate in treating allergic rhinitis, and the pharmacy type with the effect of sodium hyaluronate in treating allergic rhinitis is provided, the method for effect of sodium hyaluronate in treating allergic rhinitis is provided simultaneously.
For realizing above-mentioned purpose, realize: the application of hyaluronic acid sodium in the preparation medicine, the application in preparation treatment of allergic rhinitis medicine through following technical scheme.
The application of described hyaluronic acid sodium in the preparation medicine, the pharmaceutical dosage form of preparation treatment of allergic rhinitis is hyaluronic acid sodium nasal drop, hyaluronic acid sodium spray, hyaluronic acid sodium aerosol or hyaluronic acid sodium ointment.
Described hyaluronic acid sodium is in the application of preparation in the medicine, and the concentration of the medicament of preparation treatment of allergic rhinitis is, per 100 milliliters or per 100 restrain hyaluronic acid sodium in the agent content be the 0.05-0.5 gram.
Method with hyaluronic acid sodium spray treatment of allergic rhinitis is: patient's nasal cavity is cleaned out; Head keeps angle perpendicular to the ground or that turn forward; The nozzle of hyaluronic acid sodium medicine spray container is inserted nasal cavity; Each nostril is the 1-3 spray at every turn, sprays the 0.1-0.2 milliliter at every turn, and spray 2-4 every day.
Method with hyaluronic acid sodium nasal drop treatment of allergic rhinitis is: patient's nasal cavity is cleaned out, and head back tilts to make the nostril up, and medicine is splashed into the nostril; Each nostril is all dripped 2-3 and is dripped; Every 0.0625 milliliter, drip 2-4 every day, pinches the wing of nose after medicinal liquid splashes into for several times; And kept the nostril 5 minutes up, medicine is fully contacted with bronchia mucosal.
The method of dripping the ointment treatment of allergic rhinitis with hyaluronic acid sodium is: dip in cotton rod and get few ointment, be applied to the nasal cavity and the bridge of the nose thereof and wing of nose place, use 2-4 every day.
Below through Test Example explain of the present invention useful it.
Hyaluronic acid sodium nasal drop treatment allergic rhinitis 10 examples.Method: the patient blows nasal mucus totally before dripping medicine, when dripping medicine, and patient's layback, head hangs down backward and makes the nostril up, and the hyaluronic acid sodium nasal drop is splashed into the nostril, and every side 2-3 drips, and gently pinches the wing of nose for several times after dripping, and has a rest and gets up in 5 minutes again, and medicinal liquid is fully contacted with bronchia mucosal.Drip medicine 2-4 every day.5 days is a course of treatment.The result: the equal sensory effect of 10 routine patients is remarkable; Watery nasal discharge, nasal obstruction, rhinocnesmus alleviated in the 1st day, and idol has a sneeze symptom, played nasal cavity on the 2nd day and obviously felt unobstructed before than medication; Sneeze, watery nasal discharge, rhinocnesmus symptom do not appear basically; Bottleneck throat also feels comfortable simultaneously, and continuous use is after 5 days, and nasal cavity inspection nasal mucosa does not have edema; Lab testing has only a small amount of epithelial cell and lymphocyte in patient's nasal discharge, during with allergic rhinitis, the more acidophil of appearance, basophilic leukocyte are compared with goblet cell in the nasal discharge, belong to normal range.
Because also do not effect a radical cure the method for allergic rhinitis at present, the basic purpose of Drug therapy is: 1. alleviate sniffle; 2. eliminate the reaction of nasal mucosa inflammation; 3. improve patient and give birth to the words quality.Common drug, antiallergic class medicine, though can improve symptom, side effect is obvious; Corticosteroid formulations, prolonged application can cause various untoward reaction; Vasoconstrictor, nasal cavity topical application vasoconstrictor can make nasal mucosa vessels shrink, and swelling is alleviated; Thereby asal resistance reduces and to alleviate the nasal obstruction symptom, but it has-fixed rebound effect, can cause Secondary cases vasodilation; So medication should have restriction, effect is gradually poor after the prolonged application. impel patient's escalated dose and number of times, thereby more increase its rebound effect; Make nasal mucosa swelling develop into irreversible pathological changes, cause medicamentous rhinitis; Mastocyte membrane stabilizer medicine, sodium cromoglicate has the good preventing effect to allergic rhinitis, and is dissatisfied to stage of attack medication effect.
Clinical trial can be found out and the invention has the advantages that: hyaluronic acid sodium excavated new purposes, opened up a new application, and treatment allergic rhinitis (allergic rhinitis), nontoxic, have no side effect, curative effect is obvious.
The specific embodiment
The application of hyaluronic acid sodium in the preparation medicine, the application in preparation treatment of allergic rhinitis medicine.
The application of described hyaluronic acid sodium in the preparation medicine, the pharmaceutical dosage form of preparation treatment of allergic rhinitis is hyaluronic acid sodium nasal drop, hyaluronic acid sodium spray, hyaluronic acid sodium aerosol or hyaluronic acid sodium ointment.
Described hyaluronic acid sodium is in the application of preparation in the medicine, and the concentration of the medicament of preparation treatment of allergic rhinitis is, per 100 milliliters or per 100 restrain hyaluronic acid sodium in the agent content be the 0.05-0.5 gram.
Method with hyaluronic acid sodium spray treatment of allergic rhinitis is: patient's nasal cavity is cleaned out; Head keeps angle perpendicular to the ground or that turn forward; The nozzle of hyaluronic acid sodium medicine spray container is inserted nasal cavity; Each nostril is the 1-3 spray at every turn, sprays the 0.1-0.2 milliliter at every turn, and spray 2-4 every day.
Method with hyaluronic acid sodium nasal drop treatment of allergic rhinitis is: patient's nasal cavity is cleaned out, and head back tilts to make the nostril up, and medicine is splashed into the nostril; Each nostril is all dripped 2-3 and is dripped; Every 0.0625 milliliter, drip 2-4 every day, pinches the wing of nose after medicinal liquid splashes into for several times; And kept the nostril 5 minutes up, medicine is fully contacted with bronchia mucosal.
The method of dripping the ointment treatment of allergic rhinitis with hyaluronic acid sodium is: dip in cotton rod and get few ointment, be applied to the nasal cavity and the bridge of the nose thereof and wing of nose place, use 2-4 every day.
Illustrate method for preparing of the present invention below:
Embodiment 1 preparation hyaluronic acid sodium nasal drop
Take by weighing hyaluronic acid sodium 0.5 gram, agar 5 grams add deionized water to 1000 milliliter, are stirred to the liquid clarification, filtration sterilization, and packing promptly get per 100 milliliters and contains the hyaluronic acid sodium nasal drop that hyaluronic acid sodium 0.05 restrains.
Embodiment 2 preparation hyaluronic acid sodium nasal drop
Take by weighing hyaluronic acid sodium 0.5 gram, ethyl hydroxybenzoate 3g adds water to 100ml, stirs, and hyaluronic acid sodium is dissolved fully, and packing promptly gets nasal drop.
Embodiment 3
Take by weighing hyaluronic acid sodium 0.3 gram, add an amount of water, stir, hyaluronic acid sodium is dissolved fully; Add glycerol 1 gram, disodiumedetate 0.01 gram, stir, phosphate buffer is regulated Ph value to 5, adds water to 100 milliliters; Cobalt 60 radiation sterilizations, packing promptly gets spray.
Embodiment 4
Take by weighing hyaluronic acid sodium 0.5g, bromo geramine 0.005g adds the Ph value and is 6.5 phosphate buffer to 100 gram, through cobalt 60 radiation sterilizations, promptly gets spray.
Embodiment 5
Hyaluronic acid sodium 0.2g, phenylmercuric acetate 0.002g, glycerol 3g, disodiumedetate 0.3g, it is an amount of to add water, stirs, and adds in the ointment for preparing in advance with carbomer, stirs, and promptly gets ointment.
Claims (3)
1. the application of hyaluronic acid sodium in the preparation medicine is characterized in that: the application in preparation treatment of allergic rhinitis medicine.
2. according to the application of hyaluronic acid sodium in the preparation medicine of claim 1, it is characterized in that: the pharmaceutical dosage form of preparation treatment of allergic rhinitis is hyaluronic acid sodium nasal drop, hyaluronic acid sodium spray, hyaluronic acid sodium aerosol or hyaluronic acid sodium ointment.
3. according to the application in the preparation medicine of the hyaluronic acid sodium of claim 1, it is characterized in that: the concentration of the medicament of preparation treatment of allergic rhinitis is, per 100 milliliters or per 100 restrain hyaluronic acid sodium in the agent content be the 0.05-0.5 gram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100901672A CN102579478A (en) | 2012-03-30 | 2012-03-30 | Application of sodium hyaluronate to preparation of medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100901672A CN102579478A (en) | 2012-03-30 | 2012-03-30 | Application of sodium hyaluronate to preparation of medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579478A true CN102579478A (en) | 2012-07-18 |
Family
ID=46469083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100901672A Pending CN102579478A (en) | 2012-03-30 | 2012-03-30 | Application of sodium hyaluronate to preparation of medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579478A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108066401A (en) * | 2018-01-04 | 2018-05-25 | 蓝栋林 | A kind of drug for being used to treat rhinitis |
| CN111265590A (en) * | 2020-01-21 | 2020-06-12 | 华熙生物科技股份有限公司 | Hyaluronic acid freeze-drying preparation for nasal spray and preparation method and application thereof |
| WO2022170405A1 (en) * | 2021-02-12 | 2022-08-18 | Master Indústria E Comércio De Produtos Odontológicos E Farmacêuticos Ltda Me | Pharmaceutical composition of aqueous sodium hyaluronate in nasal spray form |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0441431A (en) * | 1990-06-04 | 1992-02-12 | Santen Pharmaceut Co Ltd | Antiallergic agent for topical administration |
| CN1602198A (en) * | 2001-12-12 | 2005-03-30 | 乌尔萨法姆药物两合公司 | Pharmaceutical composition for use in ophthalmology and rhinology |
| DE10360425A1 (en) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| CN1660441A (en) * | 2004-12-20 | 2005-08-31 | 凌沛学 | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method |
| CN102300870A (en) * | 2009-02-02 | 2011-12-28 | 大塚化学株式会社 | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same |
-
2012
- 2012-03-30 CN CN2012100901672A patent/CN102579478A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0441431A (en) * | 1990-06-04 | 1992-02-12 | Santen Pharmaceut Co Ltd | Antiallergic agent for topical administration |
| CN1602198A (en) * | 2001-12-12 | 2005-03-30 | 乌尔萨法姆药物两合公司 | Pharmaceutical composition for use in ophthalmology and rhinology |
| DE10360425A1 (en) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| CN1660441A (en) * | 2004-12-20 | 2005-08-31 | 凌沛学 | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method |
| CN102300870A (en) * | 2009-02-02 | 2011-12-28 | 大塚化学株式会社 | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same |
Non-Patent Citations (1)
| Title |
|---|
| 黄道秋等: "莫西沙星滴鼻液的研制", 《中国医院药学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108066401A (en) * | 2018-01-04 | 2018-05-25 | 蓝栋林 | A kind of drug for being used to treat rhinitis |
| CN111265590A (en) * | 2020-01-21 | 2020-06-12 | 华熙生物科技股份有限公司 | Hyaluronic acid freeze-drying preparation for nasal spray and preparation method and application thereof |
| WO2022170405A1 (en) * | 2021-02-12 | 2022-08-18 | Master Indústria E Comércio De Produtos Odontológicos E Farmacêuticos Ltda Me | Pharmaceutical composition of aqueous sodium hyaluronate in nasal spray form |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2611159B2 (en) | Hyaluronic acid pharmacologically active fraction, method for producing the same and pharmaceutical composition | |
| CN102949709B (en) | External gel used for treating diabetic foot, and preparation method and application thereof | |
| CN104080458A (en) | Products for healing of tissue wounds | |
| WO2020051117A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| CN104546896B (en) | A kind of bioactivity hyaluronic acid derivatives preparation | |
| CN107184961A (en) | A kind of competent cell renovation agent and preparation method thereof | |
| JP2012067127A (en) | Use of biocompatible polymer for the preparation of medical compound or medical device | |
| KR20120042729A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| CN102579334A (en) | Nasal drops containing sodium hyaluronate and preparation method thereof | |
| US20240082175A1 (en) | Cannabinoid and menthol transdermal delivery systems and methods | |
| CN100381169C (en) | Composite collagen eye drops | |
| CN102579478A (en) | Application of sodium hyaluronate to preparation of medicines | |
| WO2023272813A1 (en) | Temperature sensitive gel damage repair formulation and application thereof | |
| CN104906029A (en) | Nasal cavity preparation and preparing method and application thereof | |
| CN102188695B (en) | Ophthalmic gel composition | |
| US11147775B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| ES2590978T3 (en) | Biocompatible injectable products with zinc and / or saccharide salt release in the form of zinc and its uses | |
| CN105214071A (en) | A kind of size variance eye drop and preparation method thereof | |
| US11229610B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| CN110013502A (en) | A kind of composition for preventing and treating acute and chronic rhinitis, nasosinusitis | |
| CN104667262B (en) | BFGF bovine basic fibroblast growth factor externally used solution | |
| CN107596355A (en) | A kind of Medical pain easing, the exterior-applied gel subsided a swelling, brought down a fever and preparation method thereof | |
| CN110327404B (en) | Xerophthalmia moisturizing spray and preparation method thereof | |
| CN102302514B (en) | Pig blood deproteinized extract gel and preparation method thereof | |
| WO2010138095A1 (en) | Medicinal agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120718 |